# New Cannabis Group Will Help Ground Policy in Science and Patient Experience > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-medicine-group-policy/ > **Published:** 2026-03-06T11:33:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:12:14-04:00 > **Clinical Summary:** A cannabis medicine group policy is shaping federal rescheduling with clinical evidence and patient experience for safer cannabinoid therapy access. --- ✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchCBDTHCSafety Why This Matters As federal rescheduling moves forward, organizations that center both clinical evidence and patient experience could directly shape whether patients gain broader, safer, and more affordable access to cannabinoid therapies. Clinical Summary A newly formed [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) group is working to ensure that federal policy discussions around [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) are rooted in scientific evidence and shaped by real patient perspectives. This effort comes at a critical moment as rescheduling conversations advance at the federal level, creating an opening to influence how cannabis is regulated, researched, and integrated into clinical care. Bridging the gap between what patients experience at the bedside and what policymakers debate in Washington has long been a missing piece in the cannabis policy landscape. Dr. Caplan’s Take “Science without patient voice produces policy that looks good on paper but fails at the pharmacy counter.” Clinical Perspective The establishment of evidence-based frameworks for cannabinoid therapy represents a critical need as federal policy evolves and patient access expands. Healthcare providers require standardized, science-informed guidelines to navigate dosing, drug interactions, and appropriate clinical applications rather than relying on anecdotal reports or incomplete information. Integrating both rigorous clinical evidence and authentic patient experiences creates a more complete understanding of cannabinoid therapeutics than either source alone can provide. As rescheduling advances, embedding these foundational principles into policy discussions will help ensure that [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions are grounded in the best available evidence rather than regulatory uncertainty. This collaborative approach between clinicians, researchers, and patients ultimately serves to professionalize [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and improve treatment outcomes across diverse populations. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+New+Cannabis+Group+Will+Help+Ground+Policy+In+Science+And+Patient+Experience+As+...+%40drcaplan&url=https%3A%2F%2Fmarijuanamoment.net%2Fnew-cannabis-group-will-help-ground-policy-in-science-and-patient-experience-as-trumps-rescheduling-move-advances-op-ed) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fmarijuanamoment.net%2Fnew-cannabis-group-will-help-ground-policy-in-science-and-patient-experience-as-trumps-rescheduling-move-advances-op-ed) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+New+Cannabis+Group+Will+Help+Ground+Policy+In+Science+And+Patient+Experience+As+...+%E2%80%94+via+%40drcaplan.bsky.social+https%3A%2F%2Fmarijuanamoment.net%2Fnew-cannabis-group-will-help-ground-policy-in-science-and-patient-experience-as-trumps-rescheduling-move-advances-op-ed) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Daily Digest 2026-03-05](https://cedclinic.com/2026-cannabis-adolescent-brain-vulnerability/) - [Daily Digest: Last 15 Hours: Pharmaceutical Standards, Cognitive Safety, and the Gap Between Medicine and Policy — March 03, 2026](https://cedclinic.com/pharmaceutical-standardization-cannabinoid-therapeutics-2026/) - [In the Mix: 16 More Articles — February 24, 2026](https://cedclinic.com/medical-cannabis-legalization-philippines-risks-oversight/) 📰 Source: [https://marijuanamoment.net/new-cannabis-group-will-help-ground-policy-in-science-and-patient-experience-as-trumps-rescheduling-move-advances-op-ed](https://marijuanamoment.net/new-cannabis-group-will-help-ground-policy-in-science-and-patient-experience-as-trumps-rescheduling-move-advances-op-ed) Further Reading Evidence Watch[Regulatory Digest 2026-03-07](https://cedclinic.com/dea-enforcement-controlled-substances-march-2026/) CED Clinic Blog[Takedown of Recent JAMA Cannabis Review](https://cedclinic.com/jama-cannabis-review-physician-analysis/) CED Clinic Blog[Cannabis Use in Older Adults Is Rising—Now What?](https://cedclinic.com/medical-cannabis-use-in-older-adults/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) is more than a scientific pursuit—it's a pathway to better health, informed … Explore how [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) integrates science and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) to improve health outcomes and inform policy. Learn More [Trump ready to move on cannabis rescheduling (Newsletter: April 23, 2026)](https://cedclinic.com/cannabis-federal-rescheduling-clinical-implications/) Stay updated on federal cannabis rescheduling efforts and their implications for policy and patient access. [Read Update](https://cedclinic.com/cannabis-federal-rescheduling-clinical-implications/) [New research highlights growing concerns around cannabis use among young adults … – Instagram](https://cedclinic.com/cannabis-use-disorder-young-adults-concerns/) Understand emerging concerns in cannabis use among young adults to inform safer policy and clinical practice. [Explore Research](https://cedclinic.com/cannabis-use-disorder-young-adults-concerns/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).